Clinical trials: Dysmetabolic Syndrome
Diabetes Mellitus
Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the safety of TAK-559, once daily (QD), in treating subjects receiving a stable dose of insulin to control type 2 diabetes mellitus.
- Trial name
- NCT00762190
- Testing
- TAK-559 and insulin, Insulin
- Volunteers
- 348 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.
The purpose of this study is to determine the metabolic and cardiovascular effects of pioglitazone, once daily (QD), and insulin combination therapy in subjects with Type 2 Diabetes and Renal Failure.
- Trial name
- PIOren (NCT00770640)
- Testing
- Pioglitazone and insulin, Insulin
- Where
- 9 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the efficacy of pioglitazone, once daily (QD), compared to glimepiride on atherosclerotic disease measured by intravascular ultrasound.
- Trial name
- PERISCOPE (NCT00225277)
- Testing
- Pioglitazone, Glimepiride
- Where
- 79 sites in United States, Argentina and 2 more
- Volunteers
- 547 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy of pioglitazone, once daily (QD), combined with azilsartan in the treatment of subjects with Type 2 Diabetes Mellitus.
- Trial name
- NCT00762736
- Testing
- Pioglitazone and azilsartan, Pioglitazone
- Where
- 78 sites in United States, Argentina and 3 more
- Volunteers
- 704 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and pioglitazone in patients with type 2 diabetes mellitus who are inadequately controlled with diet and exercise alone.
- Trial name
- NCT00395512
- Testing
- Alogliptin, Pioglitazone
- Where
- 161 sites in United States, Argentina and 21 more
- Volunteers
- 655 people
- Sponsor
- Takeda
Diabetes Mellitus
Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with pioglitazone in adults with type 2 diabetes mellitus
- Trial name
- NCT00286494
- Testing
- Alogliptin and pioglitazone, Pioglitazone
- Where
- 77 sites in United States, Argentina and 12 more
- Volunteers
- 493 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy, safety and tolerability of SYR-472, once daily (QD), in subjects with Type 2 Diabetes Mellitus.
- Trial name
- NCT00653185
- Testing
- SYR-472
- Where
- 87 sites in United States, Chile and 10 more
- Volunteers
- 369 people
- Sponsor
- Takeda
Diabetes Mellitus, Liver
Safety Study of Pioglitazone Compared To Glyburide on Liver Function
The purpose of this study is to determine the liver safety of pioglitazone, once daily (QD), versus glyburide taken with metformin and insulin.
- Trial name
- NCT00494312
- Testing
- Pioglitazone, Glyburide
- Volunteers
- 2,120 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with metformin in adults with type 2 diabetes mellitus.
- Trial name
- NCT00286442
- Testing
- Alogliptin and metformin, Metformin
- Where
- 56 sites in United States, Argentina and 15 more
- Volunteers
- 527 people
- Sponsor
- Takeda
Diabetes Mellitus
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.
The purpose of this study is to asses changes in glycosylated hemoglobin, fasting blood lipids and genetic polymorphism's in peroxisomal proliferator activated receptors--gamma receptor after 6 months of pioglitazone, once daily…
- Trial name
- NCT00449553
- Testing
- Pioglitazone and sulphonylurea, Pioglitazone and metformin
- Where
- 4 sites in Denmark, Iceland and 2 more
- Volunteers
- 326 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes
The purpose of this study is to determine the efficacy of pioglitazone and metformin combination therapy, once daily (QD), on glycosylated hemoglobin in adults with type 2 diabetes.
- Trial name
- NCT00754403
- Testing
- Pioglitazone and metformin, Metformin
- Volunteers
- 312 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in Type 2 Diabetes subjects.
- Trial name
- NCT00763022
- Testing
- TAK-559
- Volunteers
- 302 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and effectiveness of multiple doses of TAK-379, once daily (QD), in subjects with type 2 diabetes mellitus.
- Trial name
- NCT00722917
- Testing
- TAK-379, Pioglitazone
- Where
- 8 sites in United States
- Volunteers
- 323 people
- Sponsor
- Takeda
Diabetes Mellitus
Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.
The purpose of this study is to evaluate the safety and efficacy of TAK-559, once daily (QD), taken in combination with metformin in treating subjects with type 2 diabetes mellitus
- Trial name
- NCT00762957
- Testing
- TAK-559 and metformin, Metformin
- Volunteers
- 15 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes
The purpose of this study was to determine the efficacy of pioglitazone taken with metformin on high-density lipoprotein cholesterol in subjects with Type 2 Diabetes.
- Trial name
- PRISMA (NCT00772174)
- Testing
- Pioglitazone and Metformin, Metformin
- Volunteers
- 418 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), compared to glipizide in elderly diabetic patients who have not received treatment or are on a single oral medication.
- Trial name
- NCT00707993
- Testing
- Alogliptin, Glipizide
- Where
- 80 sites in United States, Hungary and 9 more
- Volunteers
- 441 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.
The purpose of this study is to determine the efficacy of pioglitazone, twice daily (BID), combined with metformin versus pioglitazone taken alone and metformin taken alone in treating Type 2 Diabetes Mellitus.
- Trial name
- NCT00727857
- Testing
- Pioglitazone and metformin, Pioglitazone, Metformin
- Where
- 77 sites in United States, Chile and 2 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy and safety of SYR-619, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.
- Trial name
- NCT00763347
- Testing
- SYR-619, Alogliptin
- Volunteers
- 82 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease
The purpose of this study is to evaluate the cardiovascular effects of pioglitazone, once daily (QD), versus glyburide when administered to patients with type 2 diabetes mellitus and mild cardiac disease.
- Trial name
- NCT00521742
- Testing
- Pioglitazone, Glyburide
- Volunteers
- 300 people
- Sponsor
- Takeda
Diabetes Mellitus
Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia
Efficacy comparison of Pioglitazone, once daily (QD), to Rosiglitazone in participants with Type 2 Diabetes
- Trial name
- NCT00331487
- Testing
- Pioglitazone, Rosiglitazone
- Where
- 67 sites in United States
- Volunteers
- 719 people
- Sponsor
- Takeda